A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

2005 • 5,837 citations

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

2006 • 2,463 citations

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

2004 • 958 citations

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1992 • 948 citations

A Southwest Oncology Group study

1993 • 778 citations

Cancer: Principles and Practice of Oncology

2006 • 676 citations

mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes

2005 • 621 citations

mTOR-targeted therapy of cancer with rapamycin derivatives

2005 • 607 citations

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten^+/−mice

2001 • 574 citations

Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors

2006 • 507 citations

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

2004 • 504 citations

Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

2005 • 467 citations

Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281

2005 • 351 citations

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.

1979 • 280 citations

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

1993 • 264 citations

Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.

1984 • 262 citations

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282

2001 • 179 citations

Carcinoid tumors and the carcinoid syndrome

1989 • 175 citations

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours

2001 • 170 citations

Lack of Efficacy of Streptozocin and Doxorubicin in Patients With Advanced Pancreatic Endocrine Tumors

2004 • 122 citations

Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid

1994 • 91 citations

Doxorubicin, Streptozocin, and 5-Fluorouracil Chemotherapy for Patients with Metastatic Islet-Cell Carcinoma

1998 • 90 citations

A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)

2005 • 76 citations

Phase II trial of doxorubicin therapy for advanced islet cell carcinoma.

1982 • 58 citations

Differential Expression of the PTEN Tumor Suppressor Protein in Fetal and Adult Neuroendocrine Tissues and Tumors: Progressive Loss of PTEN Expression in Poorly Differentiated Neuroendocrine Neoplasms

2002 • 57 citations

Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab

2005 • 56 citations

Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results

2004 • 34 citations

Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

2005 • 26 citations

Untitled

2002 • 23 citations